Pharmacodynamics of PEG-IFN-α-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 2, 2011, Pages 95-99

  De Araújo, Evaldo Stanislau Affonso ^a   Dahari, Harel ^b   Cotler, Scott J ^b   Layden, Thomas J ^b   Neumann, Avidan U ^c   Melo, Carlos Eduardo ^a   Barone, Antonio Alci ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

HCV; HIV; IL28B; Mathematical modeling; pegylated interferon alpha 2a; pharmacodynamics; viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MATHEMATICAL MODEL; MIXED INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AMERICA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 78751634052     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182020596     Document Type: Article

References (30)

1. Arends JE, Boucher CA, Hoepelman AI. Hepatitis C virus and human immunodeficiency virus coinfection: where do we stand? Neth J Med. 2005;63:156-163.
2. Ferreira P, Navarro R. Coinfeccxcão VHC/HIV, VHB/VHC/HIV, VHC/HTLV. In: Hepatite C. 1st ed. São Paulo Manole Editing; 2010: 280-308.
3. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
5. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
6. Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS. 2004;18:59-66.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965.
8. FriedMW, ShiffmanML,ReddyKR,etal. Peginterferonalfa-2aplusribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
9. Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. J Hepatol. 2006;44(1 suppl):S40-S43.
10. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
11. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
13. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul;139(1):120-9.
14. Howell CD, Thompson AJ, Ryan K, et al. IL28B genetic variation association with early viral kinetics and SVR in HCV henotype 1 the VIRAHEP-C study. J Hepatol. 2010;52(Suppl 1):S451.
15. Neumann AU, Bibert S, Haagmans B, et al. IL28B polymorphism is significantly correlated with IFN anti-viral effectivness already on first day of pegylated interferon-a and ribavirin therapy of chronic HCV infection J Hepatol. 2010;52(Suppl 1):S468.
16. Araujo ESA, Dahari H, Neumann AU, et al. Very early prediction of response to HCV treatment with peg-IFN-alfa-2a and ribavirin in HIV/HCV coinfected patients. J Viral Hepat. 2010. In press.
17. Dahari H, Araujo E, Haagmans B, et al. Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol. 2010;53:460-467.
18. Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology. 2010;138:1240-1243.
19. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338-1345, e1331-e1337.
20. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007;46:16-21.
21. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-1358.
22. Dahari H, Shudo E, Cotler SJ, et al. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther. 2009;14:459-464.
23. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282: 103-107.
24. Mangia A, Thompson AJ, Santoro R, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821-827.
25. Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24: F23-F29.
26. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010;51: 788-795.
27. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52:33-37.
28. Araujo ESA, Melo CE, Martins LP et al. Brazilian profile of IL28-B single nucleotide polymorphism (SNP): a retrospective analysis and possible consequences for interferon-alpha based therapies. Hepatology. 2010; 52(Suppl):779A.
29. Zeuzem S, Nelson DR, Marcellin P. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care? Antivir Ther. 2008;13:747-760.
30. Boehme RE, Cameron S. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV. Antivir Ther. 2009;14:1195-1208.